---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006457"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:31:22.431820+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Contineum reports Q4 2024 net loss of $14.6M, cash $204.8M, runway through 2027

## Summary
- Net loss $14.6M in Q4 2024 vs $7.8M in Q4 2023; R&D expenses $13M (+62% YoY).
- Cash and equivalents $204.8M at Dec 31, 2024; expects to fund operations through 2027.
- Topline data from PIPE-791 Phase 1b PET trial expected Q2 2025; PIPE-307 Phase 2 RRMS data H2 2025.
- PIPE-791 Phase 2 proof-of-concept in IPF and PrMS planned H2 2025 pending toxicity studies.
- Plan to file IND for CTX-343 in H2 2025; J&J recruiting Phase 2 MDD trial of PIPE-307.

## SEC filing metadata
- accession: 0001437749-25-006457
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/0001437749-25-006457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006457/cont20250214_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006457
- JSON: https://secwatch.observer/filing/0001437749-25-006457.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006457.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.